Cargando…
CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
Tamoxifen, a selective estrogen receptor modulator, is the standard of care for premenopausal women with estrogen or progesterone receptor-positive breast cancer and a valid option for treating post-menopausal women. However, a substantial number of tamoxifen-treated patients relapse following surgi...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940141/ https://www.ncbi.nlm.nih.gov/pubmed/20877451 http://dx.doi.org/10.1371/currents.RRN1176 |